Ad is loading...
FSCCX
Price
$35.68
Change
+$0.57 (+1.62%)
Updated
Nov 22 closing price
VISVX
Price
$51.30
Change
+$0.69 (+1.36%)
Updated
Nov 22 closing price
Ad is loading...

FSCCX vs VISVX

Header iconFSCCX vs VISVX Comparison
Open Charts FSCCX vs VISVXBanner chart's image
Nuveen Small Cap Value I
Price$35.68
Change+$0.57 (+1.62%)
VolumeN/A
CapitalizationN/A
Vanguard Small Cap Value Index I
Price$51.30
Change+$0.69 (+1.36%)
VolumeN/A
CapitalizationN/A
FSCCX vs VISVX Comparison Chart
Loading...
View a ticker or compare two or three
VS
FSCCX vs. VISVX commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FSCCX is a Buy and VISVX is a Buy.

FUNDAMENTALS
Fundamentals
VISVX has more cash in the bank: 57.6B vs. FSCCX (458M). VISVX pays higher dividends than FSCCX: VISVX (1.90) vs FSCCX (0.97). FSCCX was incepted earlier than VISVX: FSCCX (30 years) vs VISVX (27 years). FSCCX is a more actively managed with annual turnover of: 31.00 vs. VISVX (16.00). VISVX has a lower initial minimum investment than FSCCX: VISVX (3000) vs FSCCX (100000). FSCCX annual gain was more profitable for investors over the last year : 34.89 vs. VISVX (30.04). VISVX (62.14) and FSCCX (60.67) have equivalent 5 years return.
FSCCXVISVXFSCCX / VISVX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence30 years27 years-
Gain YTD21.61417.712122%
Front LoadN/AN/A-
Min. Initial Investment10000030003,333%
Min. Initial Investment IRAN/AN/A-
Net Assets458M57.6B1%
Annual Yield % from dividends0.971.9051%
Returns for 1 year34.8930.04116%
Returns for 3 years17.7316.92105%
Returns for 5 years60.6762.1498%
Returns for 10 years91.89109.8384%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EFXT9.240.20
+2.21%
Enerflex Ltd
RVSN0.440.01
+1.60%
Rail Vision Ltd
CAG27.170.05
+0.18%
Conagra Brands
FULC2.97-0.02
-0.67%
Fulcrum Therapeutics
KYMR43.51-0.54
-1.23%
Kymera Therapeutics